NYSE - Nasdaq Real Time Price USD

AbbVie Inc. (ABBV)

212.30 -1.46 (-0.68%)
At close: May 20 at 4:01:44 PM EDT
212.47 +0.17 (+0.08%)
Overnight: 11:27:04 PM EDT
Trade AbbVie on Coinbase
Chart Range Bar
Loading chart for ABBV
Chart does not reflect overnight price.

News headlines AbbVie (ABBV) continues to attract attention as it navigates a dynamic market landscape. Recent reports highlight a slight adjustment in price targets while showcasing its strong revenue growth driven by immunology drugs.

AbbVie (ABBV) continues to attract attention as it navigates a dynamic market landscape. Recent reports highlight a slight adjustment in price targets while showcasing its strong revenue growth driven by immunology drugs.

Updated 34m ago · Powered by Yahoo Scout
  • Previous Close 213.76
  • Open 213.36
  • Bid 213.76 x 30000
  • Ask 213.44 x 30000
  • Day's Range 211.50 - 214.50
  • 52 Week Range 180.25 - 244.81
  • Volume 3,017,706
  • Avg. Volume 6,757,229
  • Market Cap (intraday) 375.09B
  • Beta (5Y Monthly) 0.31
  • PE Ratio (TTM) 105.10
  • EPS (TTM) 2.02
  • Earnings Date Jul 30, 2026
  • Forward Dividend & Yield 6.92 (3.26%)
  • Ex-Dividend Date Apr 15, 2026
  • 1y Target Est 252.90

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.

www.abbvie.com

57,000

Full Time Employees

December 31

Fiscal Year Ends

Performance Overview: ABBV

Trailing total returns as of 5/20/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

ABBV
5.56%
S&P 500 (^GSPC)
8.58%

1-Year Return

ABBV
18.59%
S&P 500 (^GSPC)
25.12%

3-Year Return

ABBV
62.91%
S&P 500 (^GSPC)
77.31%

5-Year Return

ABBV
118.67%
S&P 500 (^GSPC)
78.71%

Earnings Trends: ABBV

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized
 

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q1 FY26
Revenue 15B
Earnings 4.71B

Q2

FY25

Q3

FY25

Q4

FY25

Q1

FY26

0
5B
10B
15B
 

Analyst Insights: ABBV

View More

Analyst Price Targets

184.00 Low
252.90 Average
212.30 Current
328.00 High
 

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell
 

Latest Rating

Date 5/15/2026
Analyst Evercore ISI Group
Rating Action Maintains
Rating Outperform
Price Action Lowers
Price Target 236 -> 235
 

Statistics: ABBV

View More

Valuation Measures

Annual
As of 5/19/2026
  • Market Cap

    377.67B

  • Enterprise Value

    441.14B

  • Trailing P/E

    104.78

  • Forward P/E

    14.99

  • PEG Ratio (5yr expected)

    0.59

  • Price/Sales (ttm)

    6.03

  • Price/Book (mrq)

    --

  • Enterprise Value/Revenue

    7.02

  • Enterprise Value/EBITDA

    26.07

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    5.79%

  • Return on Assets (ttm)

    10.03%

  • Return on Equity (ttm)

    --

  • Revenue (ttm)

    62.82B

  • Net Income Avi to Common (ttm)

    3.6B

  • Diluted EPS (ttm)

    2.02

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    9.39B

  • Total Debt/Equity (mrq)

    --

  • Levered Free Cash Flow (ttm)

    20.81B

Compare To: ABBV

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights: ABBV

Fair Value

212.30 Current
 

Dividend Score

0 Low
Sector Avg.
100 High
 

Hiring Score

0 Low
Sector Avg.
100 High
 

Insider Sentiment Score

0 Low
Sector Avg.
100 High
 

Research Reports: ABBV

View More
  • Argus Quick Note: Weekly Stock List for 05/18/2026: Focus List Changes

    Argus has published its latest Portfolio Selector, which features its popular Focus List. Each month, Director of Research Jim Kelleher, CFA, surveys the team of Argus Research industry analysts for their timeliest recommendations out of the company's fundamental universe of approximately 500 stocks. The Focus List typically includes 30 stocks: turnover is high, as Jim typically adds three or four new stocks per month. Below are the latest additions, all of which are rated BUY at Argus.

     
  • Everything's More Expensive

    Wars -- particularly in the oil-rich Mideast -- have a way of worrying inflation watchers. In the current situation, oil prices have jumped sharply since the fighting began, and we are now seeing the impact of higher energy prices spreading to almost every sector of the economy. Let's take a look at the numbers. First, according to last week's CPI report from the Bureau of Labor Statistics (BLS), gasoline prices are up almost 30% over the past year as the price of a barrel of crude oil has soared this spring to above $100 from a low of $55 late last year. Prices in the broad energy category are up 18% in the past year, including a 6% climb in electricity prices. Moving along the value chain, transport prices are higher by 4.3%, which is an increase from the 4.1% inflation rate a month ago; and apparel prices are rising at a 4.2% pace compared to the prior month's 3.4% increase. Hungry? Food prices are going up, too. Food prices last month rose at a 3.2% rate compared to a 2.7% rate a month ago. Is anything lower? Not much, but we do note that prices for medical care services rose at "only" a 3.2% rate last month, down from 3.7% a month earlier. Maybe that's because consumers are starting to tighten their belts and are cutting back on visits to the doctor. One bright spot: used car prices are down 2.7% year over year. But it will cost you more to fill that clunker's tank.

     
  • Long-Term Optimism

    The Portfolio Selector features the Argus Focus List, a group of 30 "best idea" stocks generated and regularly updated by Argus' analysts and investment policy committee. It also includes the director of research’s monthly investment strategy column, stock recommendations and sector picks, economic forecasts, and an asset allocation model. This month, the Focus List additions are AbbVie Inc (ABBV); Applovin Corp (APP); Nokia Oyj (NOK); Ulta Beauty Inc (ULTA) and the Focus List deletions are Salesforce Inc (CRM); DoorDash Inc (DASH); International Business Machine (IBM); IQVIA Holdings Inc (IQV).

     
  • While the large cap indices make all-time highs day after day, there are

    While the large cap indices make all-time highs day after day, there are technical cracks everywhere else. This includes secondary indices, sectors, industries, and individual stocks. We have talked about poor market breadth, and perhaps the only thing we can say is that most money is invested in the mega-cap indices, so there is no problem until there is. We hear it's different this time -- and for now it certainly is. How long the AI party will last is unknown. So as we always do, we'll leave it up to price. The NYSE and the Dow Jones have not exceeded their February all-time highs (ATHs). The S&P MidCap 400 (MDY) was last at an ATH on May 6, followed by a bearish engulfing candlestick and a potential false breakout. The S&P Small Cap 600 (SML) also peaked on May 6, has been down for four of the past five days, and is sitting on important short-term support at its 21-day exponential moving average. The Nasdaq 100 has 19% of its issues at ATHs, the S&P 500 has 8%, the MDY 5%, and the SML 4%. Some 8% of the QQQ's holdings are at 52-week lows, 9% of the S&P 500 and the MDY, and 5% of the SML. The QQQ has 20% of its issues at a one-month high, the S&P 500 has 12%, the MDY 7%, and the SML 6%. Yet 24% to 27% of the issues in the four indices are at one-month lows. Since the spike began, the number of 52-week highs on the S&P 500 peaked at 51 on April 17 and has fallen to 35, while the number of new lows has climbed to 43. Coming out of the April 2025 slide, we saw 57 new highs more than three months into the rally. But during early stages of other recent recoveries, the number has been in 80 to 120 issues.

     

People Also Watch